6.91
-0.0184(-0.27%)
Currency In USD
| Previous Close | 6.93 |
| Open | 7.04 |
| Day High | 7.09 |
| Day Low | 6.9 |
| 52-Week High | 11.31 |
| 52-Week Low | 6 |
| Volume | 1.75M |
| Average Volume | 4.53M |
| Market Cap | 1.46B |
| PE | -138.23 |
| EPS | -0.05 |
| Moving Average 50 Days | 7.26 |
| Moving Average 200 Days | 8.39 |
| Change | -0.02 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $689.09 as of November 20, 2025 at a share price of $6.912. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $1,596.21 as of November 20, 2025 at a share price of $6.912.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of trea
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
GlobeNewswire Inc.
Oct 23, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma &
BioCryst to Report Third Quarter 2025 Financial Results on November 3
GlobeNewswire Inc.
Oct 20, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management wil